Alexa
  • Directory of Taiwan

Novartis wins approval for pain treatment

Novartis wins approval for pain treatment

Swiss pharmaceutical company Novartis AG said Monday its Voltaren Gel received U.S. regulatory approval as the first prescription treatment for pain associated with osteoarthritis.
The U.S. Food and Drug Administration granted the approval for Voltaren Gel, which is a nonsteroidal anti-inflammatory medication, for use in treating pain associated with osteoarthritis in joints amenable to topical treatment, such as the knees and those of the hands, the company said in a statement.
"Clinical trials have demonstrated Voltaren Gel to be highly effective in treating osteoarthritis pain in the hands and knees, which are the body's most commonly affected joints," Novartis said.
The efficacy and safety of Voltaren Gel were studied in more than 900 patients with knee or hand osteoarthritis. The US approval was based on several studies, including the results of two randomized, double-blind, placebo-controlled efficacy studies and a 12-month safety study.
Novartis shares dipped 0.3 percent to 61.45 Swiss francs (US$52.73; euro36.86) in Zurich.